Contineum Therapeutics, Inc. Class A Common Stock
$13.21
-$0.55 (-4.00%)
$12.86Day Range$14.40
Key Statistics
Market Cap
$496.98M
Shares Outstanding
37.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 5, 2024
Round Lot
100
Locale
US
Trading Data
Day Open
$14.07
Day High
$14.40
Day Low
$12.86
Volume
580.1K
VWAP
$13.39
Prev Close
$13.76
Transactions
--
Acc. Volume
--
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
PHARMACEUTICAL PREPARATIONSSIC 283451 employees3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121(858) 333-5280IPO Apr 5, 2024US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001855175
- Composite FIGI
- BBG01M27SVP6
- Share Class FIGI
- BBG01M27SWR2
- Ticker Root
- CTNM
- SIC Code
- 2834
About Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Stock
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) closed the 2026-09-17 session at $13.21, down 4.00% versus the previous close (-0.55). The stock opened at $14.07 and traded between $12.86 and $14.40 during that session. Session trading volume was 580K shares. The volume-weighted average price (VWAP) is $13.39.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Contineum Therapeutics, Inc. Class A Common Stock has a market capitalization of $497.0 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. CTNM is listed on the XNAS exchange. The company employs approximately 51 people. Contineum Therapeutics, Inc. Class A Common Stock is headquartered in SAN DIEGO, CA. The recorded listing date is 2024-04-05.
On this page you can find market CTNM stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.